Hovione, a contract development and manufacturing organization (CDMO) specializing in spray drying and particle engineering, is expanding its nasal drug delivery capabilities with the addition of a family of nasal powder delivery devices developed in partnership with Industrial Design Consultancy (IDC). 

Hovione and IDC have been working together to accelerate the development and commercialization of two new active nasal powder delivery devices, one single-use and one multidose. The devices are designed to enable broad and targeted nasal deposition flexibility while delivering maximum usability and reliability. By using standard capsules and filling equipment, they also have the potential to simplify drug product development and manufacturing.

Hovione will offer the new devices on an exclusive basis as part of its integrated offering for nasal drug development and manufacturing.

“Intranasal drug delivery is gaining momentum across a number of applications, including mucosal vaccination and CNS treatments bypassing the blood-brain barrier,” said Jean-Luc Herbeaux, Hovione’s CEO. “Our partnership with IDC, a company with vast experience in industrial design, mechanical and electronic engineering of medical devices, enables Hovione to offer a complete solution for nasal powder delivery – covering APIs, formulation, filling, analytics and device design and manufacturing,” said Herbeaux.

Stephen Knowles, IDC´s managing director said, “By combining Hovione’s capabilities in pharmaceutical development, formulation and manufacturing with IDC’s device development expertise, this partnership offers customers a nasal powder delivery solution which can be rapidly adapted to new pharma compounds and therapies. Our joint development team has done incredible work to create unique, high performance nasal powder delivery devices.”